Wolverine Blend

COMPOUND OVERVIEW

The Wolverine Blend is a precision-formulated combination of two of the most extensively studied regenerative peptides: BPC-157 (Body Protection Compound 157) and TB500 (Thymosin Beta 4). Both peptides independently demonstrate powerful tissue repair, anti-inflammatory, and regenerative properties through complementary and synergistic mechanisms. Combined in a single vial at research-grade purity, this blend represents a multi-pathway approach to studying musculoskeletal repair, wound healing, and tissue regeneration. The name ‘Wolverine’ reflects the research interest in accelerated regenerative capacity — a reference to the extraordinary tissue repair studied in animal models using both compounds.

MECHANISM OF ACTION

BPC-157 operates primarily through upregulation of growth factor receptors (including GH receptors), NO synthesis, angiogenesis, and the FAK-paxillin cell survival pathway. TB500 (Thymosin Beta 4) acts as an actin-sequestering protein that promotes cell migration, wound closure, blood vessel formation, and survival signaling through the Akt/PI3K pathway. Together, these mechanisms converge on accelerating tissue vascularization, cellular migration to injury sites, collagen matrix remodeling, and anti-inflammatory resolution. Research suggests the combination may produce additive or synergistic regenerative effects compared to either peptide administered alone.

RESEARCH APPLICATIONS

• Multi-pathway musculoskeletal injury and repair research
• Tendon, ligament, and muscle healing combination protocols
• Angiogenesis and wound vascularization research
• Anti-inflammatory and tissue recovery models
• Synergy studies between BPC-157 and TB500 mechanisms
• Gastrointestinal tissue repair and systemic cytoprotection models
• Post-surgical tissue recovery research protocols

KEY RESEARCH FINDINGS

• Individual studies on BPC-157 and TB500 have independently demonstrated accelerated tendon and muscle repair in animal models
• Research on Thymosin Beta 4 shows upregulation of Akt/PI3K survival signaling in cardiac and musculoskeletal tissue
• BPC-157 angiogenesis studies demonstrate capillary formation within 48 hours of administration in wound models
• TB500 research in cardiac injury models shows reduced fibrosis and improved contractile function
• Combined VEGF and NO pathway activation represents a multi-mechanism approach to vascularized tissue repair
• Researchers have studied combination regimens noting cumulative benefits across different injury types

STORAGE & HANDLING

• Store lyophilized at -20°C; stable up to 24 months
• Reconstitute with bacteriostatic water; store at 2–8°C; use within 28 days
• Both peptides are co-lyophilized in a single vial — reconstitute with single addition of carrier
• Avoid freeze-thaw cycling post-reconstitution
• Handle under sterile conditions with research-appropriate technique

SPECIFICATIONS

DISCLAIMER: This compound is sold strictly for laboratory and research purposes only. It is not intended for human consumption, clinical use, or veterinary application. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. For use by licensed researchers and qualified professionals only. You must be 21 years of age or older to purchase.

usaminopeptides.com · For Researcher Inquiries Contact: info@usaminopeptides.com